MABS1251
Anti-CYP11B2 Antibody, clone 41-17B
clone 41-17B, from mouse
Synonym(s):
Cytochrome P450 11B2, mitochondrial, CYP11B2, Aldosterone synthase, ALDOS, Aldosterone-synthesizing enzyme, CYPXIB2, Cytochrome P-450Aldo, Cytochrome P-450C18, Steroid 18-hydroxylase
Sign Into View Organizational & Contract Pricing
All Photos(4)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
41-17B, monoclonal
species reactivity
human
species reactivity (predicted by homology)
mouse (based on 100% sequence homology)
technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CYP11B2(1585)
General description
Cytochrome P450 11B2, mitochondrial (EC1.14.15.4, EC1.14.15.5; UniProt P19099; also known as ALDOS, Aldosterone synthase, Aldosterone-synthesizing enzyme, CYPXIB2, Cytochrome P-450Aldo, Cytochrome P-450C18, Cytochrome P450 subfamily XIB polypeptide 2, Steroid 11-beta-monooxygenase, Steroid 11-beta/18-hydroxylase, Mitochondrial cytochrome P450 family 11 subfamily B polypeptide 2) is encoded by the CYP11B2 (Also known as CPN2, CYP11B, CYP11BL, P450C18) gene in human (Gene ID 1585). CYP11B2 protein is a member of the cytochrome P450 superfamily of monooxygenases that catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP11B2 protein is localized to the mitochondrial inner membrane and exhibits steroid 18-hydroxylase activity and steroid 11 beta-hydroxylase activity. CYP11B2 gene mutations are known causes of corticosterone methyl oxidase 1 (CMO-1) deficiency, an autosomal recessive disorder of aldosterone biosynthesis.
Immunogen
Chicken serum albumin-conjugated linear peptide corresponding to human CYP11B2 near the N-terminus.
Epitope: Near N-terminus
Application
Anti-CYP11B2 Antibody, clone 41-17B is an antibody against CYP11B2 for use in Western Blotting, Immunohistochemistry, Immunofluorescence.
Immunohistochemistry Analysis: A representative lot detected CYP11B2 in normal adrenal glands (Gomez-Sanchez, C.E., et al. (2014). Mol. Cell Endocrinology. 383:111-117).
Immunofluorescence Analysis: A representative lot detected CYP11B2 in normal adrenal glands (Gomez-Sanchez, C.E., et al. (2014). Mol. Cell Endocrinology. 383:111-117).
Immunofluorescence Analysis: A representative lot detected CYP11B2 in normal adrenal glands (Gomez-Sanchez, C.E., et al. (2014). Mol. Cell Endocrinology. 383:111-117).
Research Category
Signaling
Signaling
Research Sub Category
Signaling Neuroscience
Signaling Neuroscience
Quality
Evaluated by Western Blotting in hCYP11B2-GFP-expressing HEK293 cell lysate.
Western Blotting Analysis: 2.0 µg/mL of this antibody detected CYP11B2 in 10 µg of hCYP11B2-GFP-expressing HEK293 cell lysate.
Western Blotting Analysis: 2.0 µg/mL of this antibody detected CYP11B2 in 10 µg of hCYP11B2-GFP-expressing HEK293 cell lysate.
Target description
~57 kDa observed
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kei Omata et al.
Hypertension (Dallas, Tex. : 1979), 72(4), 874-880 (2018-10-26)
Primary aldosteronism affects ≈5% to 10% of hypertensive patients and has unilateral and bilateral forms. Most unilateral primary aldosteronism is caused by computed tomography-detectable aldosterone-producing adenomas, which express CYP11B2 (aldosterone synthase) and frequently harbor somatic mutations in aldosterone-regulating genes. The
Chuanming Xu et al.
Acta physiologica (Oxford, England), 237(1), e13899-e13899 (2022-10-21)
The kaliuretic action of the renin-angiotensin-aldosterone system (RAAS) is well established as highlighted by hyperkalemia side effect of RAAS inhibitors but such action is usually ascribed to systemic RAAS. The present study addresses the involvement of intrarenal RAAS in K+
Jimmy J Mao et al.
Journal of the Endocrine Society, 5(8), bvab107-bvab107 (2021-07-15)
The detection and management of concomitant pheochromocytoma (PHEO) and primary aldosteronism (PA) is not well understood. To investigate varying presentations and outcomes of cases with coexisting PHEO and PA to provide an approach to its diagnosis and management. We conducted
Wenjuan Liu et al.
Acta pharmaceutica Sinica. B, 12(1), 135-148 (2022-02-08)
Hyperaldosteronism is a common disease that is closely related to endocrine hypertension and other cardiovascular diseases. Cytochrome P450 11B2 (CYP11B2), an important enzyme in aldosterone (ALD) synthesis, is a promising target for the treatment of hyperaldosteronism. However, selective inhibitors targeting
Kazutaka Nanba et al.
The Journal of clinical endocrinology and metabolism, 103(10), 3869-3876 (2018-08-08)
Somatic mutations have been identified in more than half of aldosterone-producing adenomas (APAs) through mutation hotspot sequencing. The underlying pathogenesis of inappropriate aldosterone synthesis in the remaining population is still unknown. To investigate the prevalence and spectrum of somatic mutations
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service